This trial is conducted globally. The aim of the trial is to evaluate cardiovascular and
other long-term outcomes with semaglutide in subjects with type 2 diabetes. The trial is
event-driven, i.e. the maximum trial duration (up to max. 148 weeks) will depend on the
accrual of major adverse cardiovascular events (MACE) in this trial and the remaining
research programme. The incidence of MACE will be monitored throughout the trial which will
be terminated according to plan when pre-specified stopping criteria are met.